Ann Clin Diabetes Endocrinol | Volume 1, Issue 1 | Research Article | Open Access
Esteghamati A, Monnavar PH, Nakhjavani M, Naraghi SP, Safari R and Mirmiranpour H*
Endocrinology and Metabolism Research Center (EMRC), Valiasr Hospital, Iran
*Correspondance to: Mirmiranpour H
Fulltext PDFBackground: Oxidative stress has been implicated in incidence of Type 2 Diabetes (T2D) and its related vascular complications. This study is aimed at investigating the comparative effect of add on glibenclamide treatment to metformin on oxidative stress markers in patients with T2D.
Materials and Methods: An open label randomized clinical trial was conducted on 95 patients (58.9% female) with T2D. Participants were allocated randomly to either metformin (1,000 mg/ day) monotherapy or add on glibenclamide (10 mg/day) to metformin (1,000 mg/day) treatment. Oxidative stress markers were investigated at baseline and following 3 months.
Results: Following just 3 months’ treatment with either metformin or metformin and glibenclamide coupled with life style modification, oxidative stress markers of observers improved significantly. Serum concentration of AGE, AOPP, MDA and Ox-LDL decreased significantly (p-value <0.001) compared to baseline.
Conclusion: In comparison with no medication, metformin in patient diabetes (p <0.05 in all analyses) the metformin monotherapy provided greater reductions than combination with glibenclamide. Three months’ treatment with Pioglitazone is beneficial in reduction anti-oxidant capacity.
Sulfonylurea compounds; Metformin; Antioxidants; Clinical trial
M, Naraghi SP, Safari R, Mirmiranpour H. Comparative Effect of Metformin Alone or in Combination with Glibenclamide on Oxidative Stress Markers of Patients with Type 2 Diabetes: A Randomized Open Clinical Trial. Ann Clin Diabetes Endocrinol. 2018; 1(1): 1007.